Stock TRDA ENTRADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
13.56 USD +2.34% Intraday chart for Entrada Therapeutics, Inc. +9.71% -10.14%
03-13 Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-13 Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oppenheimer Starts Entrada Therapeutics With Outperform Rating, Price Target is $22
MT
HC Wainwright Adjusts Entrada Therapeutics' Price Target to $20 From $25, Maintains Buy Rating
MT
HC Wainwright Starts Entrada Therapeutics at Buy With $25 Price Target
MT
Goldman Sachs Adjusts Price Target on Entrada Therapeutics to $18 From $13, Maintains Neutral Rating
MT
Goldman Sachs Adjusts Price Target on Entrada Therapeutics to $13 From $10, Keeps Neutral Rating
MT
Goldman Sachs Adjusts Entrada Therapeutics' Price Target to $10 from $22, Keeps Neutral Rating
MT
Evercore ISI Initiates Coverage on Entrada Therapeutics With Outperform Rating
MT
Cowen Starts Entrada Therapeutics at Outperform
MT
Goldman Sachs Starts Entrada Therapeutics at Neutral With $29 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRDA Stock
  4. News Entrada Therapeutics, Inc.
  5. Analyst Reco.